UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________

FORM 8-K

______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~January~~April 3119, 2018

______________

BIOSTAR PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

______________

Maryland	001-34708	20-8747899
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, People’s Republic of China 712046

Xiangyang City, Shaanxi Province, People’s Republic of China 712046

(Address of Principal Executive Office) (Zip Code)

86-029-33686638

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2 of this chapter) Emerging growth company ☐. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~Emerging~~Item ~~growth~~3.01 Notice ~~company~~of ☐.Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

IfOn anApril ~~emerging~~19, ~~growth~~2018, ~~company~~Biostar Pharmaceuticals, ~~indicate~~Inc. by(the ~~check~~“Company”) ~~mark~~received ifa notification letter from Nasdaq Listing Qualifications (“Nasdaq”) advising the ~~registrant~~Company ~~has~~that, ~~elected~~since it had not tofiled ~~use~~its ~~the~~Annual ~~extended~~Report ~~transition~~on ~~period~~Form 10-K for ~~complying~~the fiscal year ended December 31, 2017, the Company was not in compliance with ~~any~~Nasdaq ~~new~~Listing orRule ~~revised~~5250(c)(1) ~~financial~~for ~~accounting~~continued ~~standards~~listing. ~~provided~~The ~~pursuant~~Company is required within 60 calendar days of the Nasdaq notification to ~~Section~~submit ~~13(~~a) plan of compliance with the ~~Exchange~~foregoing ~~Act~~continued listing deficiency. ☐If the Company’s plan is approved by the Nasdaq staff, the Company may be eligible for a listing exception of up to 180 calendar days (or until October 15, 2018) to regain compliance. If the Nasdaq staff concludes that the Company will not be able to cure the deficiency, or if the Company determines not to submit the required materials or make the required representations, the Company’s common stock will be subject to delisting by Nasdaq.

~~Item~~Certain ~~4.01 Change~~statements in ~~Registrant~~this report that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company’s ~~Certifying~~control, ~~Accountant~~that could cause actual results to materially differ from such statements. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertake no obligation to, update or revise any forward-looking statement.

~~Resignation~~Item of8.01 ~~Mazars~~Other ~~CPA Limited~~Events

On ~~January~~April 3123, 2018, ~~Mazars~~the ~~CPA~~Company ~~Limited~~issued ~~tendered~~a ~~its~~press ~~resignation~~release asrelating ~~Biostar~~to ~~Pharmaceuticals,~~the ~~Inc.’s~~foregoing ~~independent registered public accounting firm (“Mazars”)~~event, ~~effective~~a ascopy of ~~the~~which ~~same~~is ~~date. Mazars’~~attached ~~determination~~hereto ~~not to seek re-appointment~~ as ~~the~~Exhibit ~~Company’s~~99.1 ~~independent~~and ~~auditors~~is ~~followed~~incorporated ~~its~~herein ~~policy~~by ~~to withdraw from the market in auditing public companies in the U~~reference.S.

~~Mazars~~Item ~~reported on the Company’s financial statements for the years ended as of December 31, 2016 and 2015, respectively~~9.01 The Mazars reports on the Company’s financial statements for the fiscal periods as of December 31, 2016 and 2015, respectively, did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles except that the Mazars report on the Company’s financial statements for the fiscal years ended December 31, 2016 and 2015 draw attention to (1) deposits paid for intended acquisitions, (2) uncertainty whether the Company was able to continue as a going concern as the Company had experienced a substantial decrease in sales volume which resulting a net loss for the years ended December 31, 2016 and 2015 and part of the Company’s buildings and land use rights were subject to litigation between an independent third party and the Company’s Chief Executive Officer, and the title of these buildings and land use rights had been seized by the PRC Courts so that the Company could not be sold without the Court’s permission, and that the Company previously violated its financial covenants included in certain short-term bank loans.Exhibits

During the Company’s two most recent fiscal years ended December 31, 2016 and the interim period through the effective date of Mazars’ resignation, (i) there were no disagreements with Mazars on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to Mazars’ satisfaction, would have caused it to make reference to the subject matter of such disagreements in its reports on the Company’s consolidated financial statements for such year, and (ii) there were no reportable events as defined in Item 304(a)(1)(v) of Regulation S-KNo. Title

The Company has provided Mazars with a copy of the foregoing disclosures and requested that it furnish a letter to the Securities and Exchange Commission stating whether or not it agrees with the above statements99. ~~A copy of such letter is filed as Exhibit 16.~~1 Press ~~to this Current Report on Form 8-K~~release.

Engagement of Centurion ZD CPA Limited

On January 31, 2018, the Company engaged Centurion ZD CPA Limited, located at Unit 1304, 13/F, Two Harbourfront, 22 Tak Fung Street, Hunghom, Hong Kong (“Centurion”), as its new independent registered public accounting firm to audit the Company’s financial statements for the year ended December 31, 2017 and the related consolidated statement of operations and comprehensive income, consolidated statement of equity and consolidated statement of cash flows for the year then ended; Centurion will also review the quarterly and year-to-date 2018 consolidated financial statements of the Company to be included in the Company’s quarterly filings on Form 10-Q for 2018. The engagement was reviewed, recommended and approved by the Audit Committee, and will be effective as of January 31, 2018.

During each of the Company’s two most recent fiscal years and through the date of this report, (a) the Company has not engaged Centurion as either the principal accountant to audit the Company’s financial statements, or as an independent accountant to audit a significant subsidiary of the Company and on whom the principal accountant is expected to express reliance in its report; and (b) the Company or someone on its behalf did not consult Centurion with respect to (i) either: the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Company’s financial statements, or (ii) any other matter that was either the subject of a disagreement or a reportable event as set forth in Items 304(a)(1)(iv) and (v) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

~~16.1 Mazars~~Exhibit ~~letter dated February 2, 2018~~No. Description

99.1 Press release.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Biostar Pharmaceuticals, Inc. By: /s/ Ronghua Wang Ronghua Wang, ~~Chairman~~Chief ~~and~~Executive ~~CEO~~Officer

Date: ~~February~~April 223, 2018

Filing Compare · Biostar Pharmaceuticals, Inc.